Introduction
BRK is an intracellular protein-tyrosine kinase that we have found to be present in approximately 60% of human breast tumours, whereas its expression is undetectable in either normal mammary tissue or ®broadenomas (a common form of benign breast lesion) (Mitchell et al., 1994; Barker et al., 1997) . Elevated BRK expression in breast carcinomas does not simply re¯ect dierential cell cycle pro®les of malignant versus normal mammary cells, and is probably a stable feature of the malignant phenotype in a majority of breast tumours . BRK expression in normal human tissues is relatively restricted (Lee et al., 1998; Llor et al., 1999) , and has been characterized in the gastro-intestinal tract where it is present in normal dierentiating epithelial cells. However, BRK expression appears to be elevated in colon tumours (Llor et al., 1999) . A probable murine orthologue of BRK, SIK, is also expressed in dierentiating epithelial cells (Vasioukhin et al., 1995) , and has been proposed to have a role in murine keratinocyte dierentiation (Vasioukhin and Tyner, 1997) . Like BRK, SIK expression has not been detected at any stage of mammary gland development (Llor et al., 1999) .
BRK comprises an SH3, an SH2 and a kinase domain, and its closest known human homologues are the SRC family kinases, however the lack of an obvious amino-terminal acylation site suggests that BRK should be classi®ed as being distinct from the SRC family. This is supported by the fact that BRK's ability to transform cells is regulated dierently from SRC kinases (Kamalati et al., 1996) , together with the ®nding that the structure of the brk gene is distinct from the conserved organisation of the src gene family (Mitchell et al., 1997) .
The ability of BRK to de-regulate cellular proliferation, together with its expression pattern and the known importance of other protein-tyrosine kinases in tumorigenesis (reviewed by Kolibaba and Druker, 1997) , support the hypothesis that BRK may have an important functional role in human breast tumour development. Since the majority of human breast tumours are thought to arise from mammary luminal epithelial cells, studies on the function of BRK have focused on cultured cells representative of this cell population. The HB4a cell line was derived by the immortalization of highly-puri®ed preparations of normal human mammary luminal cells (Stamps et al., 1994) , expresses low to undetectable levels of BRK, and has retained the phenotypic and growth-regulatory characteristics of its progenitor cells (Kamalati et al., 1996) . HB4a cells, as is the case with primary luminal cells, require the action of speci®c growth factors such as epidermal growth factor (EGF) for their proliferation. The experimental expression of BRK in these cells, at levels equivalent to those found in breast tumour cells, results in their sensitization to the mitogenic eects of EGF, and potentiates their ability to proliferate in an anchorage-independent manner (Kamalati et al., 1996) . The eects of BRK on proliferation are not, however, restricted to these cells, since it can sensitize the EGF-dependent mitogenic response of another luminal-like cell line (MCF10-A), and can partially transform murine NIH3T3 embryonic ®broblasts (Kamalati et al., 1996) . The BRK-induced potentiation of mammary cell mitogenesis in response to EGF may be of particular relevance, since there is extensive experimental and clinical/pathological evidence for EGF and related peptides having important roles in promoting breast tumour cell proliferation, neoplastic transformation, and breast tumour development (reviewed by Kim and Muller, 1999) .
The BRK cDNAs isolated from human breast tumour cells, and used in the functional studies described above, encode a protein identical to that encoded by genomic clones derived from normal human placental DNA (Mitchell et al., 1997) . It is therefore possible that the elevation of BRK expression levels alone could have an important functional role during breast tumour development, through imparting on mammary epithelial cells the ability to proliferate in response to limiting concentrations of growth factors such as EGF. The mechanism(s) by which BRK might achieve this is, however, unclear. BRK expression neither increases the steady-state level, surface availability, nor EGF-binding anity of the EGF receptor (EGFr), however BRK and the EGFr do form a constitutive association in mammary epithelial cells (Kamalati et al., 1996) . The aim of this study was to investigate whether BRK in¯uences the signalling events initiated by EGF in mammary luminal epithelial cells.
Results

BRK is phosphorylated on tyrosine in response to EGF
The involvement of BRK in signalling downstream of the epidermal growth factor receptor (EGFr) in mammary epithelial cells was investigated. HB4a human mammary luminal epithelial cells, transfected either with an empty vector or with one directing expression of BRK at levels equivalent to those detected in breast carcinoma cells (Kamalati et al., 1996) , were quiesced overnight, and treated with epidermal growth factor (EGF) at 100 ng/ml for 5 min. This resulted in the phosphorylation of BRK on one or more tyrosine residues (Figure 1 ). The functional signi®cance of the phosphorylation of BRK on tyrosine residues in response to EGF remains to be clari®ed however, together with the ®nding that BRK physically associates with the EGFr (Kamalati et al., 1996) , it suggested that BRK may in¯uence signalling regulated by the EGFr.
BRK expression enhances EGF-dependent phosphorylation of erbB3, and recruitment of the PI 3-kinase p85 subunit
The phosphorylation of a number of proteins known to be modi®ed by EGF signalling was investigated. Of these only erbB3, one of the four known members of the receptor family of which EGFr is the prototypical member, showed a clear dierence in its phosphorylation when BRK-expressing and control HB4a cells were compared. In quiescent BRK-expressing cells, erbB3 appeared to be slightly more phosphorylated on tyrosine residues than in control cells, however EGF stimulation resulted in signi®cantly enhanced phosphorylation of erbB3 in BRK-expressing cells (Figure 2 ). Since EGF-induced erbB3 phosphorylation can mediate recruitment of the regulatory p85 subunit of phosphoinositide 3-kinase (PI 3-kinase) (Fedi et al., 1994; Kim et al., 1994; Prigent and Gullick, 1994; Solto et al., 1994) , erbB3 immunoprecipitates were probed for the presence of p85. The amount of p85 recovered paralleled the degree of phosphorylation of erbB3, in that quiescent BRK-expressing cells had more p85 associated with erbB3 than control cells, and EGF-stimulated BRKexpressing cells had a substantially enhanced recruitment of p85 to erbB3-containing complexes when compared with stimulated control cells ( Figure 2 ).
Co-expression of BRK and erbB3 results in complex formation, and tyrosine phosphorylation of erbB3
In order to further investigate the phosphorylation of erbB3, and determine whether erbB3 and BRK interact (brk) were quiesced by culturing overnight in medium containing 0.5% FCS, and then stimulated with EGF at 100 ng/ml for 5 min. ErbB3 was immunoprecipitated from lysates of stimulated and mockstimulated cells, resolved by SDS ± PAGE, Western blotted, and probed with antibodies recognising phosphotyrosine (top panel), erbB3 (middle panel) or PI 3-kinase p85 subunit (lower panel). The mobilities of molecular weight standards are shown to the right of each panel physically, human embryonic kidney (HEK293) cells were transfected to over-express either BRK, erbB3, or both. Immunoprecipitation of erbB3 and Western blotting revealed that erbB3 over-expressed alone became only weakly phosphorylated on tyrosine ( Figure  3 ). This ®nding was consistent with the observation that, due to sequence alterations at important residues, erbB3 has a severely impaired intrinsic catalytic activity (Guy et al., 1994) . However, when BRK and erbB3 were coexpressed, erbB3 became phosphorylated on tyrosine residues and formed complexes containing BRK ( Figure  3) . A mutant of BRK with its kinase activity abolished (BRK K219M; Kamalati et al., 1996) failed to induce the phosphorylation of erbB3, but nonetheless co-precipitated with it ( Figure 3 ).
Association of PI 3-kinase activity with erbB3 is enhanced in BRK-expressing cells
In order to determine whether the recruitment of the p85 regulatory subunit to erbB3 re¯ected the association of PI 3-kinase catalytic activity, the enzymatic activity was measured directly. Control and BRK-expressing HB4a cells were quiesced, and then stimulated with EGF under the same conditions as were employed in the preceding experiments. The cells were lysed, erbB3 was immunoprecipitated, and the PI 3-kinase activity in the precipitates was determined (Table 1) . There was an increase in enzyme activity associated with erbB3 in response to EGF in both the BRK-expressing and the control cells. However, the EGF-stimulated levels were almost twofold greater in the BRK-expressing cells than in the control cells, thus con®rming that p85 recruitment was indicative of the binding of the active enzyme. The highest level of PI 3-kinase activity that was detected in erbB3 immunoprecipitates amounted to *4% of the total activity recoverable from identical cell lysates using an antibody to the p85 regulatory subunit of PI 3-kinase (data not shown).
EGF-induced phosphorylation of Akt/protein kinase B is augmented in BRK-expressing cells
An important target for regulation by the 3-phosphoinositide products of PI 3-kinase is Akt/protein kinase B (reviewed by Kandel and Hay, 1999) . The induction of Akt's kinase activity in response to PI 3-kinase activation involves the binding of phosphatidylinositol-3,4,5-trisphosphate by its Pleckstrin Homology (PH) domain, thus causing Akt to be relocated to the plasma membrane. Subsequent phosphorylation at two regulatory sites fully activates the kinase. One of these sites is phosphorylated by another PI 3-kinase target kinase (phosphoinositide-dependent kinase-1, PDK-1), and the other (serine 473) may be phosphorylated either by PDK-1 (Balendran et al., 1999) , by autophosphorylation (Toker and Newton, 2000) , or by an (as yet) unidenti®ed kinase. An antibody that recognises Akt, when phosphorylated at serine 473, was used to investigate the activation of this kinase in control and BRK-expressing HB4a cells after stimulation with EGF. Akt was not detectably phosphorylated in nonstimulated cells, whereas a low level of phosphorylation of Akt at serine 473 occurred as a result of EGFstimulation. The level of EGF-induced phosphorylation was elevated in the BRK-expressing HB4a cells, when compared with the control cells (Figure 4) .
Discussion
In these studies, the eects of BRK expression on signalling downstream of EGF have been investigated. Control (Rep) or BRK-expressing HB4a cells were starved overnight, then mock-stimulated (7) or stimulated with EGF (+) for 5 min. The cells were lysed, erbB3 was immunoprecipitated, and the amount of PI 3-kinase activity in each precipitate was measured. The ®gures shown are the mean of the results of ®ve experiments; in each case the PI 3-kinase activity associated with erbB3 in non-stimulated control cells was given the value 1. The standard deviation was calculated for each set of values The cells used in these studies closely model the cell type that is thought to progress to produce the majority of human breast cancers, and the level of BRK expression achieved in the cells is typical of that found in cultured breast carcinoma cells. The ®ndings presented in this study are, therefore, likely to provide a relevant insight into the consequences of the elevated expression of BRK in mammary epithelial cells.
Our ®ndings show that EGF stimulation results in the rapid phosphorylation of BRK on tyrosine. This may be as a result of autophosphorylation, and/or modi®cation by another kinase such as the EGFr. BRK is known to be capable of autophosphorylation, since the high-level expression of BRK in either bacteria or human cells results in its constitutive tyrosine phosphorylation, whereas a kinase-negative mutant does not become modi®ed (Mitchell et al., 1994 , MR Crompton, unpublished data). The functional relevance of BRK's tyrosine phosphorylation will be the subject of future investigations, however our observations suggest that BRK is directly involved in the early signalling events initiated by EGF.
The important roles that EGF family peptides and their receptors are likely to play in promoting the development of breast tumours are well established (reviewed by Kim and Muller, 1999) . Although EGF is currently thought to have only one necessary and sucient cell-surface signalling receptor, the EGFr, the intracellular events it elicits are also determined by the cellular expression patterns of the three other known members of the EGFr family (erbB/HER2, 3 and 4). EGF binding to its receptor not only results in the phosphorylation of the EGFr, but can also result in the increased phosphorylation of erbB2, 3 or 4 (reviewed by Riese and Stern, 1998) . This trans-modulation of receptor activation is thought to result from the liganddependent formation of receptor heterodimers or multimers, and underlies the ability of erbB3 to become phosphorylated on its intracellular domain and recruit signalling molecules in spite of possessing a severely impaired intrinsic kinase activity (Guy et al., 1994) . The phosphorylation of erbB3 in response to EGF is not fully understood, but is thought to involve the mediation of erbB2 in cells that express this orphan receptor (Graus-Porta et al., 1997) . We have found that the expression of BRK signi®cantly increases the degree to which erbB3 becomes phosphorylated in response to EGF in HB4a cells. BRK, but not a kinase-inactive mutant, was able to induce the ecient tyrosine phosphorylation of erbB3 when over-expressed in HEK293 cells, however both BRK and the kinaseinactive mutant formed a complex with erbB3. Taken together, these results suggest that BRK may be able to directly phosphorylate erbB3 in response to EGF, possibly mediated by a direct physical interaction that is independent of BRK's kinase activity. Further studies will be required to dissect the structural bases of the interactions of BRK with erbB3 and the EGFr, and to determine whether other receptors (e.g., erbB2) can also bind BRK.
A predominant route through which EGF signalling is coupled to the activation of PI 3-kinase is via the phosphorylation, on erbB3, of recruitment sites for the SH2 domains of the p85 regulatory subunit of Class I PI 3-kinases (Fedi et al., 1994; Kim et al., 1994; Prigent and Gullick, 1994; Solto et al., 1994) . In parallel with the elevated EGF-dependent phosphorylation of erbB3 in BRK-expressing cells we have detected an increased recruitment of PI 3-kinase, as measured by the detection of both p85 and enzymatic activity in erbB3 immunoprecipitates. The enhanced EGF-induced phosphorylation of Akt on serine 473 in the BRKexpressing cells is likely to be a result of increased PI 3-kinase activation, since phosphorylation at this site is not associated with the activation of Akt by the PI 3-kinase-independent mechanisms that have been studied (reviewed by Kandel and Hay, 1999) . BRK therefore makes a quantitative contribution to the coupling of EGF signalling and Akt activation via PI 3-kinase, most likely through enhanced recruitment of PI 3-kinase to erbB3. Alternatively, if other signalling routes are employed in parallel to activate PI 3-kinase, BRK may also modify some of these to account for the change in phosphorylation status detected in the total cellular pool of Akt.
These ®ndings on the role of BRK in EGF signalling could be particularly relevant when considering the cellular outcome of elevated BRK levels in breast carcinomas, since PI 3-kinase has been found to be necessary for mitogenesis in several contexts (reviewed by Rameh and Cantley, 1999; Vanhaesebroeck and Water®eld, 1999) , including insulin-like growth factor I-induced proliferation of MCF-7 breast carcinoma cells (Dufourny et al., 1997) . Thus, in the BRKexpressing HB4a cells, the increased eciency of EGFregulated PI 3-kinase recruitment could contribute to the BRK-dependent mitogenic sensitization that we have described previously (Kamalati et al., 1996) . Akt has been proposed to be one of the`downstream' mediators of PI 3-kinase's eects on mitogenesis and cell cycle progression, for example through regulating levels of cyclin D1, p27 and c-Myc (reviewed by Kandel and Hay, 1999) . In MCF-7 breast carcinoma cells, Akt activation has been proposed to have an additional contribution to proliferation in response to insulin-like growth factor, through phosphorylating the kinase Raf at an inhibitory site. This reduces activation of the ERK (extracellular signal-regulated kinase) pathway, whose prolonged activation can otherwise arrest proliferation in these cells (Zimmerman and Moelling, 1999) .
The discovery that tumour suppression by the PTEN tumour suppressor gene product probably depends on its ability to dephosphorylate PI 3-kinase products at the D3 position has highlighted the importance of the (Brk) were quiesced by culturing overnight in medium containing 0.5% FCS, and then stimulated with EGF at 100 ng/ ml for 5 min. Cell lysates from stimulated and mock-stimulated cells were resolved by SDS ± PAGE, Western blotted, and probed with an antibody that recognises Akt when phosphorylated at serine 473 (upper panel). Subsequently, the same blot was reprobed with an antibody recognising total Akt (lower panel) PI 3-kinase/Akt signal transduction pathway in human cancer (reviewed by Di Cristofano and Pandol®, 2000) . This pathway has been associated with the regulation of several biological processes other than cell proliferation, of which apoptosis is arguably the most interesting in the context of tumour development. There is now compelling evidence that activation of this pathway can protect cells from the execution of programmed cell death in response to a wide variety of stimuli (reviewed by Datta et al., 1999) . The elevation of BRK levels in breast cancers may therefore provide a selective advantage not only through accelerated proliferation, but also through a reduced likelihood of undergoing programmed cell death, whether`spontaneous' or in response to therapy. These possibilities will be investigated in future studies, with the ultimate aim of determining whether targeting BRK may provide new opportunities for treating breast cancer.
Materials and methods
Cell culture
Cultures of HB4a human mammary luminal epithelial cells transfected with control and brk cDNA expression vectors have been described previously (Kamalati et al., 1996) . These cells were maintained in RPMI 1640 medium supplemented with 10% FCS, insulin (5 mg/ml), hydrocortisone (5 mg/ml), cholera toxin (100 ng/ml) and histidinol (1 mM), and quiesced by overnight culture in RPMI 1640 medium containing only 0.5% FCS. EGF (mouse submaxillary, receptor grade, Sigma) was used at 100 ng/ml for 5 min in stimulation experiments. Human embryonic kidney (HEK293) cells were cultured in DMEM/10% FCS.
cDNA expression vectors for transient expression BRK expression vectors with cDNAs cloned in pRCCMV (Invitrogen) have been described previously (Kamalati et al., 1996) . A human erbB3 cDNA was cloned into pCDNA3 (Invitrogen).
Antibodies
The antibody to BRK used in these studies was a rat monoclonal antibody, ICR 100, described previously . The anti-phosphotyrosine antibody was RC-20 (Transduction Labs.). The rabbit antibody recognising erbB3 was obtained from Santa Cruz (sc-285). The rabbit antibody to the p85 subunit of PI 3-kinase was obtained from Upstate Biotechnology. Rabbit antibodies recognising Akt, and Akt phosphorylated at Ser-473, were purchased from New England Biolabs. HRP-conjugated antibodies to rabbit and rat immunoglobulins were obtained from Amersham and Sigma respectively.
Immunoprecipitation and Western blotting
Total cell lysates for Western blotting were prepared by lysing cell monolayers in pre-heated SDS ± PAGE sample buer. Cell lysates for immunoprecipitates were prepared in 50 mm HEPES (pH 7.4)/150 mM NaCl/5 mM MgCl 2 /1 mM EGTA/1% (v/v) Triton X-100/0.1 mg/ml Pefabloc/10 mg/ml aprotinin/5 mg/ml pepstatin/100 mM sodium¯uoride/10 mM sodium pyrophosphate/100 mM sodium orthovanadate/10% (v/v) glycerol. BRK was immunoprecipitated using the ICR 100 monoclonal antibody, rabbit anti-rat IgG bridging antibody (Sigma) and protein A-Sepharose (Sigma). ErbB3 was immunoprecipitated using a rabbit anti-erbB3 antibody bound to protein A-Sepharose. Immunoprecipitates were washed three times in 50 mM Tris (pH 8.0)/150 mM NaCl/ 5 mM EDTA. Immunoprecipitates and cell lysates were resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS ± PAGE) and electrophoretically transferred to`Hybond-ECL' membranes (Amersham). For the detection of speci®c proteins, blots were blocked in PBS/5% (w/v) non-fat dried milk overnight (or in PBS/20% (w/v) non-fat dried milk for 2 h), antibody incubations were in PBS/10% (v/v) calf serum, and washes were in PBS/0.1% (v/ v) Tween-20. For the detection of protein phosphorylation, blots were blocked in TBS/1% (w/v) bovine serum albumin (Sigma)/0.1% (v/v) Tween-20, antibody incubations were in the same buer, and washes were in TBS/0.1% (v/v) Tween-20. HRP-conjugated antibodies were detected using enhanced chemiluminescence (ECL) reagents (Amersham).
PI-3-kinase assay
The assay for PI 3-kinase activity was carried out essentially as described by Whitman et al. (1995) . Brie¯y, following immunoprecipitation, the protein-A-Sepharose bound immune complexes were washed once with ice-cold PBS, twice with 100 mM Tris (pH 7.4)/0.5 M LiCl and then ®nally twice with 10 mM Tris (pH 7.4)/100 mM NaCl/1 mM EDTA. The immune complexes were preincubated for 20 min at 48C with 10 ml of 1 mg/ml (0.2 mg/ml ®nal) phosphatidylinositol (dispersed by sonication in 5 mM HEPES (pH 8.0)). The reaction was started by addition of 50 mM ATP, 5 mM MgCl 2 and 2 mCi [g-32 P]ATP/assay in a ®nal volume of 50 ml. The reaction was incubated at 258C for 20 min and terminated by the addition of 100 ml of 1 M HCl. Lipids were extracted with 200 ml of chloroform/methanol (1 : 1). The organic phase was washed once with 80 ml of methanol/HCl (1 : 1) and then spotted on a Silica gel 60 TLC plate pretreated with 1% (w/v) oxalic acid. Phosphorylated lipids were separated in a chloroform/methanol/4 M NH 4 OH (9 : 7 : 2) solvent. Phosphorylated lipids were visualised and quantitated using a Phosphorimager (Molecular Dynamics). Standard lipids were visualized by exposure to iodine vapour.
